NCT04166942View on ClinicalTrials.gov

KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 11, 2019

Primary Completion Date

June 6, 2022

Study Completion Date

June 6, 2022

Conditions

Hepatic Impairment

Interventions

DRUG

KD025

Single dose of 200 mg KD025 orally

Trial Locations (5)

32810

Omega Research Group, Orlando

33147

Advanced Pharma CR, LLC, Miami

78215

The Liver Institute, San Antonio

92377

Inland Empire Clinical Trials, LLC-HQ, Rialto

33014-3616

Clinical Pharmacology of Miami, Miami

All Listed Sponsors

lead

Kadmon, a Sanofi Company

INDUSTRY

NCT04166942 - KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment | Biotech Hunter | Biotech Hunter